Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation.
Research output: Contribution to journal › Article
Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2) -associated breast and ovarian cancers. We evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-associated cancers.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||Journal of Clinical Oncology|
|Publication status||Published - 2015|